Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Janux Therapeutics

Explore full profile

Developing unique immunotherapies that generate tumor-specific immune responses to attack and kill tumors without destroying a patient’s healthy tissue

San Diego, United StatesFounded 2017Biotech & Life Sciences
Valuation $1.02B Market cap · 2026
Revenue $32M Latest reported FY

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies designed to treat cancer. The company specializes in creating tumor-activated immunotherapies that stimulate the immune system within the tumor microenvironment, aiming to attack and kill tumors without harming healthy tissue. Janux employs its proprietary platform masking technology to engineer novel drug candidates that address the traditional limitations of T cell engagers, such as toxicity and efficacy issues. The primary clients are cancer patients, and the company operates within the biopharmaceutical market. Janux's business model revolves around advancing its drug candidates through clinical trials, with the goal of obtaining regulatory approval and subsequently commercializing these therapies. Revenue is generated through partnerships, licensing agreements, and eventually, the sale of approved therapies. Currently, Janux is actively recruiting for its Phase 1 clinical trial, ENGAGER PSMA 01, to evaluate the safety and efficacy of its lead candidate, JANX007, in patients with metastatic prostate cancer.

Source: Dealroom company data

At a glance

Status
Listed
Founded
2017
Headquarters
San Diego, United States
Listing
IPO 2021
Sector
Biotech & Life Sciences
Power Law
Unicorn$1–10B valuation tierColt$25–100M revenue

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Investors

19 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A12 investors entered at this stage

Series B and later7 investors entered at this stage

  • Logos Capital
  • Janus Henderson Investors
  • BVF Partners
  • Hartford HealthCare Endowment
  • Samsara BioCapital
  • EcoR1 Capital
  • Citadel

Talent

Book a demo to see the people
Team profiled 9 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown
Web traffic by country
8.7K monthly visits
across markets
🇺🇸 United States83.9%
🇮🇳 India9.2%
🇬🇧 United Kingdom8%
Top 3 markets shown

Patents

Estimated portfolio value
$4M

30 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Janux Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Janux Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles